yttrium-90 (90Y)-clivatuzumab tetraxetan enters Phase III for Pancreatic Cancer- Immunomedics.
Immunomedics has announced first patient dosing in the Company's Phase III registration study of its Pancreatic Cancer drug, yttrium-90 (90Y)-clivatuzumab tetraxetan. The PANcreatic Cancer RadioImmunotherapy Trial-1 (PANCRIT-1) is a double-blind, randomized study aimed to evaluate the safety and efficacy of 90Y-clivatuzumab tetraxetan combined with low-dose gemcitabine and best supportive care in patients with metastatic Pancreatic Cancer who have received at least two prior therapies, one of which must have been a gemcitabine-containing regimen. The primary endpoint of this study is overall survival (OS).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.